Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Open-Label Phase 2 Study of ARC-520 in Chronic Hepatitis B
2015-005499-46Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Apr 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARC-520 in Chronic Hepatitis B (CHB), sponsored by Arrowhead Pharmaceuticals. Started Apr 2016; status: terminated.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2015-005499-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005499-46.